glp-1/gcgr dual agonist Schematic illustration of monoagonists, agonists and triple GLP-1R, GIPR and GCGR Cell

Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-l randomized clinical trial

Weight loss can include lean mass, especially if calorie intake drops without adequate protein and resistance training

Oral semaglutide was superior to placebo, sitagliptin, and liraglutide and similar to empagliflozin, with losses up to 4.44 kg compared with 0.53.6 kg for active-comparator arms and 0.41.4 kg compared with placebo [35,36,37,38,39,40]

This happens to some GLP-1 users who get full fast and might not eat enough food to get all the protein their body needs, causing a problem: losing valuable muscle along with fat

Meta-analyses conclude that GLP-1 RAs improve metabolic and hormonal parameters in PCOS, though the direct contribution to live birth rates remains uncertain

Bowel Obstruction: Studies show a link between Trulicity and an increased risk of bowel obstruction, particularly for those new to the medication (had been taking the drug for less than one month)